Wall Street Zen Upgrades bioAffinity Technologies (NASDAQ:BIAF) to Hold

bioAffinity Technologies (NASDAQ:BIAF) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of bioAffinity Technologies in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

bioAffinity Technologies Stock Performance

NASDAQ:BIAF opened at $3.92 on Friday. The firm has a market capitalization of $17.64 million, a P/E ratio of -0.25 and a beta of -0.82. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.60 and a quick ratio of 2.58. bioAffinity Technologies has a one year low of $0.69 and a one year high of $25.83. The company’s 50-day simple moving average is $1.84 and its 200 day simple moving average is $2.06.

bioAffinity Technologies (NASDAQ:BIAF) last released its earnings results on Saturday, March 14th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.70) by $1.59. bioAffinity Technologies had a negative net margin of 241.93% and a negative return on equity of 301.67%. The firm had revenue of $1.59 million during the quarter, compared to analyst estimates of $1.55 million.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Sabby Management LLC bought a new position in shares of bioAffinity Technologies in the third quarter worth approximately $719,000. Scientech Research LLC purchased a new position in bioAffinity Technologies in the 3rd quarter worth approximately $49,000. Finally, Geode Capital Management LLC purchased a new position in bioAffinity Technologies in the 4th quarter worth approximately $36,000. 1.64% of the stock is owned by hedge funds and other institutional investors.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.